Tumor necrosis factor-α gene polymorphism in severe and mild-moderate rheumatoid arthritis

Journal of Rheumatology

Volumn 29, Issue 1, 2002, Pages 29-33

  Fabris, M ^a   Di Poi, E ^a   D'Elia, A ^a   Damante, G ^a   Sinigaglia, L ^a   Ferraccioli, G ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Disease susceptibility; Rheumatoid arthritis; Tumor necrosis factor gene

Indexed keywords

CYCLOSPORIN A; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GENETIC SCREENING; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036138727     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Xenobiotics or biological response modifiers? Methotrexate remains the anchor drug for rheumatoid arthritis
2. Methotrexate and emerging therapies
3. Methotrexate in rheumatoid arthritis: An update
4. Randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
5. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis-the Methotrexate-Cyclosporine Combination Study Group
6. Treatment with a chimeric monoclonal antibody to tumor necrosis factor suppresses disease activity in rheumatoid arthritis: Results of a multicenter randomized, double blind trial
7. Infliximab and methotrexate in the treatment of RA
8. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
9. Biologic therapy for rheumatoid arthritis
10. Updated consensus statement on tumor necrosis factor blocking agents for the treatment of rheumatoid arthritis
11. Prognostic factors in rheumatoid arthritis
12. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis: A prospective follow-up study of 147 patients
13. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
14. Discriminating ability of composite indices for measuring disease activity in RA: A comparison of the chronic arthritis systemic index, disease activity score and Thompson's articular index
15. Can we develop simple response criteria for slow-activity antirheumatic drugs?
16. Functional analysis of a human tumor necrosis factor-α promoter polymorphism related to joint damage in rheumatoid arthritis
17. Association of the TNF +489 polymorphism with susceptibility and radiographic damage in rheumatoid arthritis
18. Tumour necrosis factor gene polymorphisms as severity markers in rheumatoid arthritis
19. Tumor necrosis factor-α gene polymorphisms in rheumatoid arthritis: Association with susceptibility to, or severity of, disease?
20. A polymorphic variation in a putative regulation box of the TNFA promoter region
21. Polymorphism in both X and Y box motifs controls level of expression of HLA-DRB 1 genes
22. Y-box binding trans-regulatory nuclear proteins and susceptibility to rheumatoid arthritis
23. The activity of the CCAAT-box binding factor NF-Y is modulated through the regulated expression of its A subunit during monocyte to macrophage differentiation: Regulation of tissue-specific genes through a ubiquitous transcription factor
24. Identification and characterization of a novel repressor site in human tumor necrosis factor-α gene
25. Human tumor necrosis factor-α gene 3' untranslated region confers inducible toxin responsiveness to homologous promoter in monocyte THP-1 cells
26. Effects of a polymorphism in the human tumor necrosis factor-α on transcription activation
27. Polymorphism of the human TNF-α promoter random variation or functional diversity?